 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements |
| What is claimed is: 1. An antibacterial compound of formula V-L-W-X; wherein: V is a glycopeptide ... |
|
| Recombinant allergenic proteins from ragweed pollen |
| The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or ... |
|
| Nucleic acids encoding allergenic proteins from ragweed |
| The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or ... |
|
| Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| OF THE INVENTION As used herein and in the claims, the term "animal" means mammals and avians, ... |
|
| Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
| What is claimed is: 1. An isolated and purified DNA molecule encoding a hybrid protein, said hybrid ... |
|
| Lentiviral packaging constructs |
| OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, ... |
|
| Method for measuring no synthase activity |
| OF THE INVENTION In the context of the present invention the following definitions apply: I... |
|
| Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| In one aspect, the present invention pertains to the discovery herein that Wnt polypeptides ("Wnts")... |
|
|
Antisense modulation of telomeric repeat binding factor 1 expression
| Details |
Inventors: Monia, Brett P.; Cowsert, Lex M.;
Assignee: Isis Pharmaceuticals Inc. (Carlsbad, CA)
Primary Examiner: Elliott; George C.
Assistant Examiner: Schmidt; Mary Melissa
Attorney, Agent or Firm: Law Offices of Jane Massey Licata
Antisense compounds, compositions and methods are provided for modulating the expression of Telomeric Repeat Binding Factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Telomeric Repeat Binding Factor 1. Methods of using these compounds for modulation of Telomeric Repeat Binding Factor 1 expression and for treatment of diseases associated with expression of Telomeric Repeat Binding Factor 1 are provided. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Telomeric Repeat Binding Factor 1, ultimately modulating the amount of Telomeric Repeat Binding Factor 1 produced.
This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding Telomeric Repeat Binding Factor 1.
As used herein, the terms "target nucleic acid" and "nucleic acid encoding Telomeric Repeat Binding Factor 1" encompass DNA encoding Telomeric Repeat Binding Factor 1, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid.
This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense".
The functions of DNA to be interfered with include replication and transcription.
The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA.
The overall effect of such interference with target nucleic acid function is modulation of the expression of Telomeric Repeat Binding Factor 1.
In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.
In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target, It is preferred to target specific nucleic acids for antisense.
"Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process
|
| Related patents |
|
|
Antisense modulation of interleukin-5 signal transduction
OF THE INVENTION The present invention comprehends antisense compounds capable of modulating IL-5 signal transduction, preferably by modulating expression of IL-5 or IL-...
|
|
|
Antisense modulation of P38 mitogen activated protein kinase expression
OF THE INVENTION p38 MAPKs play an important role in signal transduction in response to cytokines, growth factors and other cellular stimuli. Specific responses ...
|
|
|
Antisense modulation of CD44 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of Smad7 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of nucleolin expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of hnRNP A1 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of E2F transcription factor 3 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of rank expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of protein kinase C-theta expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense oligonucleotide modulation of human mdm2 expression
OF THE INVENTION Tumors often result from genetic changes in cellular regulatory genes. Among the most important of these are the tumor suppressor genes, of which p53 ...
|
|
|
Gene Therapy 
